Biomarkers in diabetic retinopathy

Review of Diabetic Studies

Volumn 12, Issue 1-2, 2015, Pages 159-195

  Jenkins, Alicia J ^a,b,c   Joglekar, Mugdha V ^a   Hardikar, Anandwardhan A ^a   Keech, Anthony C ^a   O’Neal, David N ^a,c   Januszewski, Andrzej S ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

AGE; Diabetic retinopathy; Electroretinogram; Macular edema; Mydriatic retinal photography

Indexed keywords

BIOLOGICAL MARKER; CONNECTIVE TISSUE GROWTH FACTOR; CXCL9 CHEMOKINE; CYTOKINE; ERYTHROPOIETIN; HEMOGLOBIN A1C; HIGH MOBILITY GROUP B PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PIGMENT EPITHELIUM DERIVED FACTOR; PLACENTAL GROWTH FACTOR; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VITAMIN D;

ANALYTICAL PARAMETERS; ANGIOGENESIS; AUTOFLUORESCENCE; BLOOD PRESSURE MONITORING; BODY MASS; CONFOCAL MICROSCOPY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; ELECTRORETINOGRAPHY; EPIGENETICS; GLUCOSE BLOOD LEVEL; GLYCEMIC VARIABILITY; HEALTH CARE SYSTEM; HEMOGLOBIN GLYCATION INDEX; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); METABOLOMICS; OBESITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINAL THICKNESS; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); VISUAL ACUITY; COMPLICATION; DISEASE COURSE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY;

BIOMARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; HUMANS;

EID: 84982728059     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2015.12.159     Document Type: Review

References (316)

1. IDF. 6th Atlas IDF, International Diabetes Federation, Diabetes Atlas, 2011.
2. Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol 2012. 60(5):428-431.
3. Elahy M, Baindur-Hudson S, Cruzat VF, Newsholme P, Dass CR. Mechanisms of PEDF-mediated protection against reactive oxygen species damage in diabetic retinopathy and neuropathy. J Endocrinol 2014. 222(3):R129-R139.
4. Qing S, Yuan S, Yun C, Hui H, Mao P, Wen F, Ding Y, Liu Q. Serum miRNA biomarkers serve as a fingerprint for proliferative diabetic retinopathy. Cell Physiol Biochem 2014. 34(5):1733-1740.
5. Diabetes: Australian facts 2008. WELFARE A I O H A, Editor 2008, Diabetes series no. 8. Cat. no. CVD 40. Canberra: AIHW.
6. Elamin A, Altahir H, Ismail B, Tuvemo T. Clinical pattern of childhood type 1 (insulin-dependent) diabetes mellitus in the Sudan. Diabetologia 1992. 35(7):645-648.
7. Buchanan TA, Xiang AH, Page KA. Gestational diabetes mellitus: risks and management during and after pregnancy. Nat Rev Endocrinol 2012. 8(11):639-649.
8. Grunwald JE, Ying GS, Maguire M, Pistilli M, Daniel E, Alexander J, Whittock-Martin R, Parker C, Mohler E, Lo JC, et al. Association between retinopathy and cardiovascular disease in patients with chronic kidney disease (from the Chronic Renal Insufficiency Cohort (CRIC) Study). Am J Cardiol 2012. 110(2):246-253.
9. Hahr AJ, Molitch ME. Diabetes, cardiovascular risk and nephropathy. Cardiol Clin 2010. 28(3):467-475.
10. Son JW, Jang EH, Kim MK, Kim IT, Roh YJ, Baek KH, Song KH, Yoon KH, Cha BY, Lee KW, et al. Diabetic retinopathy is associated with subclinical atherosclerosis in newly diagnosed type 2 diabetes mellitus. Diabetes Res Clin Pract 2011. 91(2):253-259.
11. Guidelines for Diabetic Retinopathy Management. 2008. https://www.nhmrc.gov.au/_files_nhmrc/publications/attac hments/di15.pdf.
12. Constantino MI, Molyneaux L, Limacher-Gisler F, Al-Saeed A, Luo C, Wu T, Twigg SM, Yue DK, Wong J. Long-term complications and mortality in youngonset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care 2013. 36(12):3863-3869.
13. Eppens MC, Craig ME, Cusumano J, Hing S, Chan AK, Howard NJ, Silink M, Donaghue KC. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care 2006. 29(6):1300-1306.
14. Wong J, Constantino M, Yue DK. Morbidity and mortality in young-onset type 2 diabetes in comparison to type 1 diabetes: where are we now? Curr Diab Rep 2015. 15(1):566.
15. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012. 35(3):556-564.
16. Kyto JP, Harjutsalo V, Forsblom C, Hietala K, Summanen PA, Groop PH. Decline in the cumulative incidence of severe diabetic retinopathy in patients with type 1 diabetes. Diabetes Care 2011. 34(9):2005-2007.
17. Evans JR, Michelessi M, Virgili G. Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database Syst Rev 2014. 11:CD011234.
18. Martinez-Zapata MJ, Marti-Carvajal AJ, Sola I, Pijoan JI, Buil-Calvo JA, Cordero JA, Evans JR. Antivascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database Syst Rev 2014. 11:CD008721.
19. Simo R, Hernandez C. Advances in the medical treatment of diabetic retinopathy. Diabetes Care 2009. 32(8):1556-1562.
20. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001. 69(3):89-95.
21. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease-six year follow-up experience. The Framingham Study. Ann Intern Med 1961. 55:33-50.
22. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993. 329(14):977-986.
23. Januszewski AS, Karschimkus C, Davis KE, O’Neal D, Ward G, Jenkins AJ. Plasma 1,5 anhydroglucitol levels, a measure of short-term glycaemia: assay assessment and lower levels in diabetic vs. non-diabetic subjects. Diabetes Res Clin Pract 2012. 95(1):e17-e19.
24. Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, Wanner C, Al-Rubeaan K, Aronson R, Barzon I, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation 2014. 129(9):999-1008.
25. Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, Klein RL. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004. 45(3):910-918.
26. Lopes-Virella MF, Baker NL, Hunt KJ, Lyons TJ, Jenkins AJ, Virella G. High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes. Diabetes Care 2012. 35(6):1333-1340.
27. Torok Z, Peto T, Csosz E, Tukacs E, Molnar A, Maros-Szabo Z, Berta A, Tozser J, Hajdu A, Nagy V, et al. Tear fluid proteomics multimarkers for diabetic retinopathy screening. BMC Ophthalmol 2013. 13(1):40.
28. Torok Z, Peto T, Csosz E, Tukacs E, Molnar AM, Berta A, Tozser J, Hajdu A, Nagy V, Domokos B, et al. Combined methods for diabetic retinopathy screening, using retina photographs and tear fluid proteomics biomarkers. J Diabetes Res 2015. 2015:623619.
29. Schwartzman ML, Iserovich P, Gotlinger K, Bellner L, Dunn MW, Sartore M, Grazia Pertile M, Leonardi A, Sathe S, Beaton A, et al. Profile of lipid and protein autacoids in diabetic vitreous correlates with the progression of diabetic retinopathy. Diabetes 2010. 59(7):1780-1788.
30. Australian absolute cardiovascular disease risk calculator: http://www.cvdcheck.org.au/.
31. Soedamah-Muthu SS, Vergouwe Y, Costacou T, Miller RG, Zgibor J, Chaturvedi N, Snell-Bergeon JK, Maahs DM, Rewers M, Forsblom C, et al. Predicting major outcomes in type 1 diabetes: a model development and validation study. Diabetologia 2014. 57(11):2304-2314.
32. Unger FT, Witte I, David KA. Prediction of individual response to anticancer therapy: historical and future perspectives. Cell Mol Life Sci 2015. 72(4):729-757.
33. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008. 115(11):1859-1868.
34. Stratton IM, Aldington SJ, Taylor DJ, Adler AI, Scanlon PH. A simple risk stratification for time to development of sight-threatening diabetic retinopathy. Diabetes Care 2013. 36(3):580-585.
35. Taylor-Phillips S, Mistry H, Leslie R, Todkill D, Tsertsvadze A, Connock M, Clarke A. Extending the diabetic retinopathy screening interval beyond 1 year: systematic review. Br J Ophthalmol 2015. In press.
36. Aspelund T, Thornorisdottir O, Olafsdottir E, Gudmundsdottir A, Einarsdottir AB, Mehlsen J, Einarsson S, Palsson O, Einarsson G, Bek T, et al. Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. Diabetologia 2011. 54(10):2525-2532.
37. Price LD, Au S, Chong NV. Optomap ultrawide field imaging identifies additional retinal abnormalities in patients with diabetic retinopathy. Clin Ophthalmol 2015. 9:527-531.
38. Silva PS, Cavallerano JD, Haddad NM, Kwak H, Dyer KH, Omar AF, Shikari H, Aiello LM, Sun JK, Aiello LP. Peripheral lesions identified on ultrawide field imaging predict increased risk of diabetic retinopathy progression over 4 years. Ophthalmology 2015. 122(5):949-956.
39. De Clerck EE, Schouten JS, Berendschot TT, Kessels AG, Nuijts RM, Beckers HJ, Schram MT, Stehouwer CD, Webers CA. New ophthalmologic imaging techniques for detection and monitoring of neurodegenerative changes in diabetes: a systematic review. Lancet Diabetes Endocrinol 2015. 3(8):653-663.
40. Virgili G, Menchini F, Casazza G, Hogg R, Das RR, Wang X, Michelessi M. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst Rev 2015. 1:CD008081.
41. Nguyen TT, Wong TY. Retinal vascular changes and diabetic retinopathy. Curr Diab Rep 2009. 9(4):277-283.
42. Pescosolido N, Barbato A, Stefanucci A, Buomprisco G. Role of electrophysiology in the early diagnosis and follow-up of diabetic retinopathy. J Diabetes Res 2015. 2015:319692.
43. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987. 36(7):808-812.
44. Jenkins A, O’Neal D. The legacy effect in type 2 diabetes. Diabetes Manag (Lond) 2010. 30:6-7.
45. Thomas MC. Glycemic exposure, glycemic control, and metabolic karma in diabetic complications. Adv Chronic Kid ney Dis 2014. 21(3):311-317.
46. Aiello LP, Sun W, Das A, Gangaputra S, Kiss S, Klein R, Cleary PA, Lachin JM, Nathan DM. Intensive diabetes therapy and ocular surgery in type 1 diabetes. N Engl J Med 2015. 372(18):1722-1733.
47. Lachin JM, White NH, Hainsworth DP, Sun W, Cleary PA, Nathan DM. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes 2015. 64(2):631-642.
48. White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008. 126(12):1707-1715.
49. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008. 359(15):1577-1589.
50. Genuth S, Sun W, Cleary P, Gao X, Sell DR, Lachin J, Monnier VM. Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. Diabetes 2015. 64(1):266-278.
51. Cencioni C, Spallotta F, Greco S, Martelli F, Zeiher AM, Gaetano C. Epigenetic mechanisms of hyperglycemic memory. Int J Biochem Cell Biol 2014. 51:155-158.
52. Miao F, Chen Z, Genuth S, Paterson A, Zhang L, Wu X, Li SM, Cleary P, Riggs A, Harlan DM, et al. Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes 2014. 63(5):1748-1762.
53. Jermendy G. Vascular memory: can we broaden the concept of the metabolic memory? Cardiovasc Diabetol 2012. 11:44.
54. Jenkins AJ, Steele JS, Janus ED, Best JD. Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria. Diabetes 1991. 40(6):787-790.
55. Jenkins AJ, Steele JS, Janus ED, Santamaria JD, Best JD. Plasma apolipoprotein (a) is increased in type 2 (noninsulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1992. 35(11):1055-1059.
56. Lee P, Jenkins A, Bourke C, Santamaria J, Paton C, Janus E, Best J. Prothrombotic and antithrombotic factors are elevated in patients with type 1 diabetes complicated by microalbuminuria. Diabet Med 1993. 10(2):122-128.
57. Agardh E, Lundstig A, Perfilyev A, Volkov P, Freiburghaus T, Lindholm E, Ronn T, Agardh CD, Ling C. Genome-wide analysis of DNA methylation in subjects with type 1 diabetes identifies epigenetic modifications associated with proliferative diabetic retinopathy. BMC Med 2015. 13:182.
58. Burdon KP, Fogarty RD, Shen W, Abhary S, Kaidonis G, Appukuttan B, Hewitt AW, Sharma S, Daniell M, Essex RW, et al. Genome-wide association study for sight-threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene. Diabetologia 2015. 58(10):2288-2297.
59. Hosseini SM, Boright AP, Sun L, Canty AJ, Bull SB, Klein BE, Klein R, Paterson AD. The association of previously reported polymorphisms for microvascular complications in a meta-analysis of diabetic retinopathy. Hum Genet 2015. 134(2):247-257.
60. Kwak SH, Park KS. Genetic studies on diabetic microvascular complications: focusing on genome-wide association studies. Endocrinol Metab (Seoul) 2015. 30(2):147-158.
61. Jenkins AJ, Zhang SX, Rowley KG, Karschimkus CS, Nelson CL, Chung JS, O’Neal DN, Januszewski AS, Croft KD, Mori TA, et al. Increased serum pigment epithelium-derived factor is associated with microvascular complications, vascular stiffness and inflammation in Type 1 diabetes. Diabet Med 2007. 24(12):1345-1351.
62. Li S, Fu XA, Zhou XF, Chen YY, Chen WQ. Angiogenesis-related cytokines in serum of proliferative diabetic retinopathy patients before and after vitrectomy. Int J Ophthalmol 2012. 5(6):726-730.
63. Boehm BO, Lang G, Feldmann B, Kurkhaus A, Rosinger S, Volpert O, Lang GK, Bouck N. Proliferative diabetic retinopathy is associated with a low level of the natural ocular anti-angiogenic agent pigment epitheliumderived factor (PEDF) in aqueous humor. A pilot study. Horm Metab Res 2003. 35(6):382-386.
64. Boehm BO, Lang G, Volpert O, Jehle PM, Kurkhaus A, Rosinger S, Lang GK, Bouck N. Low content of the natural ocular anti-angiogenic agent pigment epitheliumderived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologia 2003. 46(3):394-400.
65. McAuley AK, Sanfilippo PG, Hewitt AW, Liang H, Lamoureux E, Wang JJ, Connell PP. Vitreous biomarkers in diabetic retinopathy: a systematic review and meta-analysis. J Diabetes Complications 2014. 28(3):419-425.
66. Yasuda M, Shimura M, Kunikata H, Kanazawa H, Yasuda K, Tanaka Y, Konno H, Takahashi M, Kokubun T, Maruyama K, et al. Relationship of skin autofluorescence to severity of retinopathy in type 2 diabetes. Curr Eye Res 2015. 40(3):338-345.
67. Januszewski AS, Sachithanandan N, Karschimkus C, O’Neal DN, Yeung CK, Alkatib N, Jenkins AJ. Noninvasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with a noninvasive measure of vascular dysfunction. Diabet Med 2012. 29(6):726-733.
68. Araszkiewicz A, Naskret D, Zozulinska-Ziolkiewicz D, Pilacinski S, Uruska A, Grzelka A, Wegner M, Wierusz-Wysocka B. Skin autofluorescence is associated with carotid intima-media thickness, diabetic microangiopathy, and long-lasting metabolic control in type 1 diabetic patients. Results from Poznan Prospective Study. Microvasc Res 2015. 98:62-67.
69. Genevieve M, Vivot A, Gonzalez C, Raffaitin C, Barberger-Gateau P, Gin H, Rigalleau V. Skin autofluorescence is associated with past glycaemic control and complications in type 1 diabetes mellitus. Diabetes Metab 2013. 39(4):349-354.
70. Hirano T, Iesato Y, Toriyama Y, Imai A, Chiba D, Murata T. Correlation between diabetic retinopathy severity and elevated skin autofluorescence as a marker of advanced glycation end-product accumulation in type 2 diabetic patients. J Diabetes Complications 2014. 28(5):729-734.
71. Noordzij MJ, Mulder DJ, Oomen PH, Brouwer T, Jager J, Castro Cabezas M, Lefrandt JD, Smit AJ. Skin autofluorescence and risk of micro-and macrovascular complications in patients with type 2 diabetes mellitus-a multicentre study. Diabet Med 2012. 29(12):1556-1561.
72. Tanaka K, Tani Y, Asai J, Nemoto F, Kusano Y, Suzuki H, Hayashi Y, Asahi K, Nakayama M, Miyata T, et al. Skin autofluorescence is associated with severity of vascular complications in Japanese patients with type 2 diabetes. Diabet Med 2012. 29(4):492-500.
73. http://www.lkc.com/products/RETeval/index-nonus.html.
74. Brzovic-Saric V, Landeka I, Saric B, Barberic M, Andrijasevic L, Cerovski B, Orsolic N, Dikic D. Levels of selected oxidative stress markers in the vitreous and serum of diabetic retinopathy patients. Mol Vis 2015. 21:649-664.
75. Costagliola C, Romano V, De Tollis M, Aceto F, dell’Omo R, Romano MR, Pedicino C, Semeraro F. TNF-alpha levels in tears: a novel biomarker to assess the degree of diabetic retinopathy. Mediators Inflamm 2013. 2013:629529.
76. Nguyen-Khuong T, Everest-Dass AV, Kautto L, Zhao Z, Willcox MD, Packer NH. Glycomic characterization of basal tears and changes with diabetes and diabetic retinopathy. Glycobiology 2015. 25(3):269-283.
77. von Thunund Hohenstein-Blaul N, Funke S, Grus FH. Tears as a source of biomarkers for ocular and systemic diseases. Exp Eye Res 2013. 117:126-137.
78. McNair P, Nielsen SL, Christiansen C, Axelsson C. Gross errors made by routine blood sampling from two sites using a tourniquet applied at different positions. Clin Chim Acta 1979. 98(1-2):113-118.
79. Kroll MH, Elin RJ. Interference with clinical laboratory analyses. Clin Chem 1994. 40(11 Pt 1):1996-2005.
80. Hofer SE, Bennetts B, Chan AK, Holloway B, Karschimkus C, Jenkins AJ, Silink M, Donaghue KC. Association between PON 1 polymorphisms, PON activity and diabetes complications. J Diabetes Complications 2006. 20(5):322-328.
81. Garcia ME, Blanco JL, Caballero J, Gargallo-Viola D. Anticoagulants interfere with PCR used to diagnose invasive aspergillosis. J Clin Microbiol 2002. 40(4):1567-1568.
82. Juhan-Vague I, Alessi MC, Fossat C, Declerck PJ, Kruithof EK. Plasma determination of plasminogen activator inhibitor 1 antigen must be performed in blood collected on antiplatelet/anticoagulant mixture. Thromb Haemost 1987. 58(4):1096.
83. Kruithof EK, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987. 70(5):1645-1653.
84. Degenhardt TP, Grass L, Reddy S, Thorpe SR, Diamandis EP, Baynes JW. Technical note. The serum concentration of the advanced glycation end-product N epsilon-(carboxymethyl)lysine is increased in uremia. Kidney Int 1997. 52(4):1064-1067.
85. Farr RJ, Januszewski AS, Joglekar MV, Liang H, McAulley AK, Hewitt AW, Thomas HE, Loudovaris T, Kay TW, Jenkins A, et al. A comparative analysis of high-throughput platforms for validation of a circulating microRNA signature in diabetic retinopathy. Sci Rep 2015. 5:10375.
86. https://www.abdserotec.com/helpful-elisa-hints.html.
87. Looker HC, Nyangoma SO, Cromie DT, Olson JA, Leese GP, Philip S, Black MW, Doig J, Lee N, Briggs A, et al. Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. Diabetologia 2013. 56(8):1716-1725.
88. Stefansson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E. Screening and prevention of diabetic blindness. Acta Ophthalmol Scand 2000. 78(4):374-385.
89. Thomas RL, Dunstan FD, Luzio SD, Chowdhury SR, North RV, Hale SL, Gibbins RL, Owens DR. Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. Br J Ophthalmol 2015. 99(1):64-68.
90. Silva PS, Cavallerano JD, Sun JK, Soliman AZ, Aiello LM, Aiello LP. Peripheral lesions identified by mydriatic ultrawide field imaging: distribution and potential impact on diabetic retinopathy severity. Ophthalmology 2013. 120(12):2587-2595.
91. Wessel MM, Aaker GD, Parlitsis G, Cho M, D’Amico DJ, Kiss S. Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy. Retina 2012. 32(4):785-791.
92. Shi L, Wu H, Dong J, Jiang K, Lu X, Shi J. Telemedicine for detecting diabetic retinopathy: a systematic review and meta-analysis. Br J Ophthalmol 2015. 99(6):823-831.
93. Kohner EM. The retinal blood flow in diabetes. Diabete Metab 1993. 19(5):401-404.
94. Kohner EM, Hamilton AM, Saunders SJ, Sutcliffe BA, Bulpitt CJ. The retinal blood flow in diabetes. Diabetologia 1975. 11(1):27-33.
95. Kohner EM, Patel V, Rassam SM. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes 1995. 44(6):603-607.
96. Lockhart CJ, McCann AJ, Pinnock RA, Hamilton PK, Harbinson MT, McVeigh GE. Multimodal functional and anatomic imaging identifies preclinical microvascular abnormalities in type 1 diabetes mellitus. Am J Physiol Heart Circ Physiol 2014. 307(12):H1729-H1736.
97. Bursell SE, Clermont AC, Kinsley BT, Simonson DC, Aiello LM, Wolpert HA. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci 1996. 37(5):886-897.
98. Ciulla TA, Harris A, Latkany P, Piper HC, Arend O, Garzozi H, Martin B. Ocular perfusion abnormalities in diabetes. Acta Ophthalmol Scand 2002. 80(5):468-477.
99. Klein R, Klein BE, Moss SE, Wong TY, Hubbard L, Cruickshanks KJ, Palta M. Retinal vascular abnormalities in persons with type 1 diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVIII. Ophthalmology 2003. 110(11):2118-2125.
100. Schmetterer L, Wolzt M. Ocular blood flow and associated functional deviations in diabetic retinopathy. Diabetologia 1999. 42(4):387-405.
101. Klein R, Myers CE, Lee KE, Gangnon R, Klein BE. Changes in retinal vessel diameter and incidence and progression of diabetic retinopathy. Arch Ophthalmol 2012. 130(6):749-755.
102. Frederiksen CA, Jeppesen P, Knudsen ST, Poulsen PL, Mogensen CE, Bek T. The blood pressure-induced diameter response of retinal arterioles decreases with increasing diabetic maculopathy. Graefes Arch Clin Exp Ophthalmol 2006. 244(10):1255-1261.
103. Jeppesen P, Knudsen ST, Poulsen PL, Hessellund A, Schmitz O, Bek T. Acute hyperinsulinemia increases the contraction of retinal arterioles induced by elevated blood pressure. Am J Physiol Heart Circ Physiol 2013. 305(11):H1600-H1604.
104. Pedersen L, Jeppesen P, Knudsen ST, Poulsen PL, Bek T. Improvement of mild retinopathy in type 2 diabetic patients correlates with narrowing of retinal arterioles. A prospective observational study. Graefes Arch Clin Exp Ophthalmol 2014. 252(10):1561-1567.
105. Meeking DR, Cummings MH, Thorne S, Donald A, Clarkson P, Crook JR, Watts GF, Shaw KM. Endothelial dysfunction in type 2 diabetic subjects with and without microalbuminuria. Diabet Med 1999. 16(10):841-847.
106. Wilson AM, O’Neal D, Nelson CL, Prior DL, Best JD, Jenkins AJ. Comparison of arterial assessments in low and high vascular disease risk groups. Am J Hypertens 2004. 17(4):285-291.
107. McVeigh GE. Arterial compliance in hypertension and diabetes mellitus. Am J Nephrol 1996. 16(3):217-222.
108. Bek T, Hajari J, Jeppesen P. Interaction between flickerinduced vasodilatation and pressure autoregulation in early retinopathy of type 2 diabetes. Graefes Arch Clin Exp Ophthalmol 2008. 246(5):763-769.
109. Pemp B, Garhofer G, Weigert G, Karl K, Resch H, Wolzt M, Schmetterer L. Reduced retinal vessel response to flicker stimulation but not to exogenous nitric oxide in type 1 diabetes. Invest Ophthalmol Vis Sci 2009. 50(9):4029-4032.
110. Nguyen TT, Kawasaki R, Wang JJ, Kreis AJ, Shaw J, Vilser W, Wong TY. Flicker light-induced retinal vasodilation in diabetes and diabetic retinopathy. Diabetes Care 2009. 32(11):2075-2080.
111. Lecleire-Collet A, Audo I, Aout M, Girmens JF, Sofroni R, Erginay A, Le Gargasson JF, Mohand-Said S, Meas T, Guillausseau PJ, et al. Evaluation of retinal function and flicker light-induced retinal vascular response in normotensive patients with diabetes without retinopathy. Invest Ophthalmol Vis Sci 2011. 52(6):2861-2867.
112. Nguyen TT, Kawasaki R, Kreis AJ, Wang JJ, Shaw J, Vilser W, Wong TY. Correlation of light-flicker-induced retinal vasodilation and retinal vascular caliber measurements in diabetes. Invest Ophthalmol Vis Sci 2009. 50(12):5609-5613.
113. Noonan JE, Dusting GJ, Nguyen TT, Jenkins AJ, Man RE, Best WJ, Dias DA, Jayasinghe NS, Roessner U, Lamoureux EL. Flicker light-induced retinal vasodilation is unaffected by inhibition of epoxyeicosatrienoic acids and prostaglandins in humans. Invest Ophthalmol Vis Sci 2014. 55(10):7007-7013.
114. Hammer M, Vilser W, Riemer T, Mandecka A, Schweitzer D, Kuhn U, Dawczynski J, Liemt F, Strobel J. Diabetic patients with retinopathy show increased retinal venous oxygen saturation. Graefes Arch Clin Exp Ophthalmol 2009. 247(8):1025-1030.
115. Hardarson SH. Retinal oximetry. Acta Ophthalmol 2013. 91(5):489-490.
116. Hardarson SH, Stefansson E. Retinal oxygen saturation is altered in diabetic retinopathy. Br J Ophthalmol 2012. 96(4):560-563.
117. Jorgensen CM, Hardarson SH, Bek T. The oxygen saturation in retinal vessels from diabetic patients depends on the severity and type of vision-threatening retinopathy. Acta Ophthalmol 2014. 92(1):34-39.
118. Ikram MK, Cheung CY, Lorenzi M, Klein R, Jones TL, Wong TY. Retinal vascular caliber as a biomarker for diabetes microvascular complications. Diabetes Care 2013. 36(3):750-759.
119. Wong TY. Retinal vessel diameter as a clinical predictor of diabetic retinopathy progression: time to take out the measuring tape. Arch Ophthalmol 2011. 129(1):95-96.
120. Rand LI, Krolewski AS, Aiello LM, Warram JH, Baker RS, Maki T. Multiple factors in the prediction of risk of proliferative diabetic retinopathy. N Engl J Med 1985. 313(23):1433-1438.
121. Goldberg M, Fine S. Symposium on the treatment of diabetic retinopathy. Airlie House, Department of Health E a W, Editor 1968: Warrenton, VA, USA, 1-913.
122. Alibrahim E, Donaghue KC, Rogers S, Hing S, Jenkins AJ, Chan A, Wong TY. Retinal vascular caliber and risk of retinopathy in young patients with type 1 diabetes. Ophthalmology 2006. 113(9):1499-1503.
123. Benitez-Aguirre P, Craig ME, Cass HG, Sugden CJ, Jenkins AJ, Wang JJ, Cusumano J, Hodgson LA, Lee K, Wong TY, et al. Sex differences in retinal microvasculature through puberty in type 1 diabetes: are girls at greater risk of diabetic microvascular complications? Invest Ophthalmol Vis Sci 2015. 56(1):571-577.
124. Cheung N, Rogers SL, Donaghue KC, Jenkins AJ, Tikellis G, Wong TY. Retinal arteriolar dilation predicts retinopathy in adolescents with type 1 diabetes. Diabetes Care 2008. 31(9):1842-1846.
125. Tsai AS, Wong TY, Lavanya R, Zhang R, Hamzah H, Tai ES, Cheung CY. Differential association of retinal arteriolar and venular caliber with diabetes and retinopathy. Diabetes Res Clin Pract 2011. 94(2):291-298.
126. Broe R, Rasmussen ML, Frydkjaer-Olsen U, Olsen BS, Mortensen HB, Hodgson L, Wong TY, Peto T, Grauslund J. Retinal vessel calibers predict long-term microvascular complications in type 1 diabetes: the Danish Cohort of Pediatric Diabetes 1987 (DCPD1987). Diabetes 2014. 63(11):3906-3914.
127. Klein R, Klein BE, Moss SE, Wong TY, Hubbard L, Cruickshanks KJ, Palta M. The relation of retinal vessel caliber to the incidence and progression of diabetic retinopathy: XIX: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol 2004. 122(1):76-83.
128. Roy MS, Klein R, Janal MN. Retinal venular diameter as an early indicator of progression to proliferative diabetic retinopathy with and without high-risk characteristics in African Americans with type 1 diabetes mellitus. Arch Ophthalmol 2011. 129(1):8-15.
129. Liew G, Sim DA, Keane PA, Tan AG, Mitchell P, Wang JJ, Wong TY, Fruttiger M, Tufail A, Egan CA. Diabetic macular ischaemia is associated with narrower retinal arterioles in patients with type 2 diabetes. Acta Ophthalmol 2015. 93(1):e45-e51.
130. Klein R, Klein BE, Moss SE, Wong TY. Retinal vessel caliber and microvascular and macrovascular disease in type 2 diabetes: XXI: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 2007. 114(10):1884-1892.
131. Grauslund J, Hodgson L, Kawasaki R, Green A, Sjolie AK, Wong TY. Retinal vessel calibre and microand macrovascular complications in type 1 diabetes. Diabetologia 2009. 52(10):2213-2217.
132. Brazionis L, Yau J, Rowley K, Itsiopoulos C, O’Dea K, Wong TY, Jenkins A. Plasminogen activator inhibitor-1 (PAI-1) activity and retinal vascular calibre in type 2 diabetes. Diabetes Res Clin Pract 2010. 87(2):192-199.
133. Benitez-Aguirre P, Craig ME, Sasongko MB, Jenkins AJ, Wong TY, Wang JJ, Cheung N, Donaghue KC. Retinal vascular geometry predicts incident retinopathy in young people with type 1 diabetes: a prospective cohort study from adolescence. Diabetes Care 2011. 34(7):1622-1627.
134. Benitez-Aguirre PZ, Sasongko MB, Craig ME, Jenkins AJ, Cusumano J, Cheung N, Wong TY, Donaghue KC. Retinal vascular geometry predicts incident renal dysfunction in young people with type 1 diabetes. Diabetes Care 2012. 35(3):599-604.
135. Cheung N, Donaghue KC, Liew G, Rogers SL, Wang JJ, Lim SW, Jenkins AJ, Hsu W, Li Lee M, Wong TY. Quantitative assessment of early diabetic retinopathy using fractal analysis. Diabetes Care 2009. 32(1):106-110.
136. Lim SW, Cheung N, Wang JJ, Donaghue KC, Liew G, Islam FM, Jenkins AJ, Wong TY. Retinal vascular fractal dimension and risk of early diabetic retinopathy: A prospective study of children and adolescents with type 1 diabetes. Diabetes Care 2009. 32(11):2081-2083.
137. Sasongko MB, Wang JJ, Donaghue KC, Cheung N, Benitez-Aguirre P, Jenkins A, Hsu W, Lee ML, Wong TY. Alterations in retinal microvascular geometry in young type 1 diabetes. Diabetes Care 2010. 33(6):1331-1336.
138. Sasongko MB, Wong TY, Donaghue KC, Cheung N, Jenkins AJ, Benitez-Aguirre P, Wang JJ. Retinal arteriolar tortuosity is associated with retinopathy and early kidney dysfunction in type 1 diabetes. Am J Ophthalmol 2012. 153(1):176-183.
139. Bringmann A, Wiedemann P. Muller glial cells in retinal disease. Ophthalmologica 2012. 227(1):1-19.
140. Feng Y, Busch S, Gretz N, Hoffmann S, Hammes HP. Crosstalk in the retinal neurovascular unit-lessons for the diabetic retina. Exp Clin Endocrinol Diabetes 2012. 120(4):199-201.
141. Metea MR, Newman EA. Glial cells dilate and constrict blood vessels: a mechanism of neurovascular coupling. J Neurosci 2006. 26(11):2862-2870.
142. Metea MR, Newman EA. Signalling within the neurovascular unit in the mammalian retina. Exp Physiol 2007. 92(4):635-640.
143. Simo R, Hernandez C. Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab 2014. 25(1):23-33.
144. Parisi V, Uccioli L. Visual electrophysiological responses in persons with type 1 diabetes. Diabetes Metab Res Rev 2001. 17(1):12-18.
145. Han Y, Adams AJ, Bearse MA Jr, Schneck ME. Multifocal electroretinogram and short-wavelength automated perimetry measures in diabetic eyes with little or no retinopathy. Arch Ophthalmol 2004. 122(12):1809-1815.
146. Harrison WW, Bearse MA Jr, Ng JS, Jewell NP, Barez S, Burger D, Schneck ME, Adams AJ. Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Invest Ophthalmol Vis Sci 2011. 52(2):772-777.
147. Sun JK, Radwan SH, Soliman AZ, Lammer J, Lin MM, Prager SG, Silva PS, Aiello LB, Aiello LP. Neural retinal disorganization as a robust marker of visual acuity in current and resolved diabetic macular edema. Diabetes 2015. 64(7):2560-2570.
148. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998. 317(7160):703-713.
149. Lind M, Oden A, Fahlen M, Eliasson B. The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects. Diabetologia 2010. 53(6):1093-1098.
150. Snell-Bergeon JK, Wadwa RP. Hypoglycemia, diabetes, and cardiovascular disease. Diabetes Technol Ther 2012. 14(Suppl 1):S51-S58.
151. Kilpatrick ES, Rigby AS, Atkin SL, Frier BM. Does severe hypoglycaemia influence microvascular complications in Type 1 diabetes? An analysis of the Diabetes Control and Complications Trial database. Diabet Med 2012. 29(9):1195-1198.
152. Feldman-Billard S, Dupas B, Sedira N, Bitu J, Erginay A, Guillausseau PJ, Massin P. Hypoglycaemia is associated with the absence of a decrease in diurnal macular thickness in patients with diabetic macular oedema. Diabetes Metab 2013. 39(2):169-173.
153. Cavalot F. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes. Diabetes Obes Metab 2013. 15(Suppl 2):3-8.
154. McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care 2004. 27(6):1259-1264.
155. Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 2010. 12(4):288-298.
156. Lachin JM, Genuth S, Nathan DM, Rutledge BN. The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial. Diabetes 2007. 56(7):1913-1921.
157. Cosson E, Banu I, Cussac-Pillegand C, Chen Q, Chiheb S, Jaber Y, Nguyen MT, Charnaux N, Valensi P. Glycation gap is associated with macroproteinuria but not with other complications in patients with type 2 diabetes. Diabetes Care 2013. 36(7):2070-2076.
158. Nayak AU, Nevill AM, Bassett P, Singh BM. Association of glycation gap with mortality and vascular complications in diabetes. Diabetes Care 2013. 36(10):3247-3253.
159. Szwergold BS, Beisswenger PJ. Enzymatic deglycation-a new paradigm or an epiphenomenon? Biochem Soc Trans 2003. 31(Pt 6):1428-1432.
160. Conner JR, Beisswenger PJ, Szwergold BS. Some clues as to the regulation, expression, function, and distribution of fructosamine-3-kinase and fructosamine-3-kinase-related protein. Ann N Y Acad Sci 2005. 1043:824-836.
161. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996. 271(17):9982-9986.
162. Jenkins AJ, Best JD, Klein RL, Lyons TJ. Lipoproteins, glycoxidation and diabetic angiopathy. Diabetes Metab Res Rev 2004. 20(5):349-368.
163. Jenkins AJ, Rowley KG, Lyons TJ, Best JD, Hill MA, Klein RL. Lipoproteins and diabetic microvascular complications. Curr Pharm Des 2004. 10(27):3395-3418.
164. Stitt AW, Jenkins AJ, Cooper ME. Advanced glycation end products and diabetic complications. Expert Opin Investig Drugs 2002. 11(9):1205-1223.
165. Du M, Wu M, Fu D, Yang S, Chen J, Wilson K, Lyons TJ. Effects of modified LDL and HDL on retinal pigment epithelial cells: a role in diabetic retinopathy? Diabetologia 2013. 56(10):2318-2328.
166. Fu D, Wu M, Zhang J, Du M, Yang S, Hammad SM, Wilson K, Chen J, Lyons TJ. Mechanisms of modified LDL-induced pericyte loss and retinal injury in diabetic retinopathy. Diabetologia 2012. 55(11):3128-3140.
167. Yu JY, Lyons TJ. Modified lipoproteins in diabetic retinopathy: a local action in the retina. J Clin Exp Ophthalmol 2013. 4(6):314.
168. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO, Smit AJ. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004. 47(7):1324-1330.
169. Kerkeni M, Saidi A, Bouzidi H, Ben Yahya S, Hammami M. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy. Microvasc Res 2012. 84(3):378-383.
170. Sugisawa E, Miura J, Iwamoto Y, Uchigata Y. Skin autofluorescence reflects integration of past long-term glycemic control in patients with type 1 diabetes. Diabetes Care 2013. 36(8):2339-2345.
171. Liu C, Xu L, Gao H, Ye J, Huang Y, Wu M, Xie T, Ni P, Yu X, Cao Y, Lu S. The association between skin autofluorescence and vascular complications in Chinese patients with diabetic foot ulcer: an observational study done in Shanghai. Int J Low Extrem Wounds 2015. 14(1):28-36.
172. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachin J, Genuth S. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999. 48(4):870-880.
173. Orchard TJ, Lyons TJ, Cleary PA, Braffett BH, Maynard J, Cowie C, Gubitosi-Klug RA, Way J, Anderson K, Barnie A, et al. The association of skin intrinsic fluorescence with type 1 diabetes complications in the DCCT/EDIC study. Diabetes Care 2013. 36(10):3146-3153.
174. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005. 54(11):3103-3111.
175. Monnier VM, Sell DR, Strauch C, Sun W, Lachin JM, Cleary PA, Genuth S. The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. J Diabetes Complications 2013. 27(2):141-149.
176. Dong N, Shi H, Xu B, Cai Y. Increased plasma S100A12 levels are associated with diabetic retinopathy and prognostic biomarkers of macrovascular events in type 2 diabetic patients. Invest Ophthalmol Vis Sci 2015. 56(8):4177-4185.
177. Zong H, Ward M, Madden A, Yong PH, Limb GA, Curtis TM, Stitt AW. Hyperglycaemia-induced proinflammatory responses by retinal Muller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia 2010. 53(12):2656-2666.
178. Barile GR, Pachydaki SI, Tari SR, Lee SE, Donmoyer CM, Ma W, Rong LL, Buciarelli LG, Wendt T, Horig H, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005. 46(8):2916-2924.
179. Moore TC, Moore JE, Kaji Y, Frizzell N, Usui T, Poulaki V, Campbell IL, Stitt AW, Gardiner TA, Archer DB, Adamis AP. The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci 2003. 44(10):4457-4464.
180. Li G, Tang J, Du Y, Lee CA, Kern TS. Beneficial effects of a novel RAGE inhibitor on early diabetic retinopathy and tactile allodynia. Mol Vis 2011. 17:3156-3165.
181. McVicar CM, Ward M, Colhoun LM, Guduric-Fuchs J, Bierhaus A, Fleming T, Schlotterer A, Kolibabka M, Hammes HP, Chen M, Stitt AW. Role of the receptor for advanced glycation endproducts (RAGE) in retinal vasodegenerative pathology during diabetes in mice. Diabetologia 2015. 58(5):1129-1137.
182. Sasongko MB, Wong TY, Nguyen TT, Kawasaki R, Jenkins A, Shaw J, Wang JJ. Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids. Diabetes Care 2011. 34(2):474-479.
183. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, Hoogwerf BJ, Miller D. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996. 114(9):1079-1084.
184. van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Polak BC. Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study. Diabetes Care 2002. 25(8):1320-1325.
185. Klein R, Sharrett AR, Klein BE, Moss SE, Folsom AR, Wong TY, Brancati FL, Hubbard LD, Couper D. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study. Ophthalmology 2002. 109(7):1225-1234.
186. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008. 371(9607):117-125.
187. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004. 364(9435):685-696.
188. Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007. 370(9600):1687-1697.
189. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010. 363(3):233-244.
190. Noonan JE, Jenkins AJ, Ma JX, Keech AC, Wang JJ, Lamoureux EL. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes 2013. 62(12):3968-3975.
191. Simo R, Roy S, Behar-Cohen F, Keech A, Mitchell P, Wong TY. Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Curr Med Chem 2013. 20(26):3258-3266.
192. Song W, Barth JL, Yu Y, Lu K, Dashti A, Huang Y, Gittinger CK, Argraves WS, Lyons TJ. Effects of oxidized and glycated LDL on gene expression in human retinal capillary pericytes. Invest Ophthalmol Vis Sci 2005. 46(8):2974-2982.
193. Barth JL, Yu Y, Song W, Lu K, Dashti A, Huang Y, Argraves WS, Lyons TJ. Oxidised, glycated LDL selectively influences tissue inhibitor of metalloproteinase-3 gene expression and protein production in human retinal capillary pericytes. Diabetologia 2007. 50(10):2200-2208.
194. Diffley JM, Wu M, Sohn M, Song W, Hammad SM, Lyons TJ. Apoptosis induction by oxidized glycated LDL in human retinal capillary pericytes is independent of activation of MAPK signaling pathways. Mol Vis 2009. 15:135-145.
195. Song W, Barth JL, Lu K, Yu Y, Huang Y, Gittinger CK, Argraves WS, Lyons TJ. Effects of modified lowdensity lipoproteins on human retinal pericyte survival. Ann N Y Acad Sci 2005. 1043:390-395.
196. Wu M, Yang S, Elliott MH, Fu D, Wilson K, Zhang J, Du M, Chen J, Lyons T. Oxidative and endoplasmic reticulum stresses mediate apoptosis induced by modified LDL in human retinal Muller cells. Invest Ophthalmol Vis Sci 2012. 53(8):4595-4604.
197. Klein RL, Hammad SM, Baker NL, Hunt KJ, Al Gadban MM, Cleary PA, Virella G, Lopes-Virella MF. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism 2014. 63(10):1287-1295.
198. Knudsen ST, Jeppesen P, Frederiksen CA, Andersen NH, Bek T, Ingerslev J, Mogensen CE, Poulsen PL. Endothelial perturbation: a link between non-dipping and retinopathy in type 2 diabetes? J Am Soc Hypertens 2007. 1(3):208-215.
199. Magri CJ, Xuereb RG, Fava S. Non-dipping heart rate and microalbuminuria in type 2 diabetes mellitus. Cardiology 2014. 129(1):28-35.
200. Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev 2015. 1:CD006127.
201. Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res 2009. 104(1):124-133.
202. Semeraro F, Cancarini A, dell’Omo R, Rezzola S, Romano MR, Costagliola C. Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res 2015. 2015:582060.
203. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res 2011. 30(5):343-358.
204. Valle A, Giamporcaro GM, Scavini M, Stabilini A, Grogan P, Bianconi E, Sebastiani G, Masini M, Maugeri N, Porretti L, et al. Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes 2013. 62(6):2072-2077.
205. Xu H, Chen M, Forrester JV. Para-inflammation in the aging retina. Prog Retin Eye Res 2009. 28(5):348-368.
206. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004. 18(12):1450-1452.
207. Chibber R, Ben-Mahmud BM, Chibber S, Kohner EM. Leukocytes in diabetic retinopathy. Curr Diabetes Rev 2007. 3(1):3-14.
208. Talahalli R, Zarini S, Tang J, Li G, Murphy R, Kern TS, Gubitosi-Klug RA. Leukocytes regulate retinal capillary degeneration in the diabetic mouse via generation of leukotrienes. J Leukoc Biol 2013. 93(1):135-143.
209. Chen Y, Hu Y, Lin M, Jenkins AJ, Keech AC, Mott R, Lyons TJ, Ma JX. Therapeutic effects of PPARalpha agonists on diabetic retinopathy in type 1 diabetes models. Diabetes 2013. 62(1):261-272.
210. Bouma G, Lam-Tse WK, Wierenga-Wolf AF, Drexhage HA, Versnel MA. Increased serum levels of MRP-8/14 in type 1 diabetes induce an increased expression of CD11b and an enhanced adhesion of circulating monocytes to fibronectin. Diabetes 2004. 53(8):1979-1986.
211. Devaraj S, Tobias P, Jialal I. Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Cytokine 2011. 55(3):441-445.
212. Josefsen K, Nielsen H, Lorentzen S, Damsbo P, Buschard K. Circulating monocytes are activated in newly diagnosed type 1 diabetes mellitus patients. Clin Exp Immunol 1994. 98(3):489-493.
213. Woo SJ, Ahn SJ, Ahn J, Park KH, Lee K. Elevated systemic neutrophil count in diabetic retinopathy and diabetes: a hospital-based cross-sectional study of 30,793 Korean subjects. Invest Ophthalmol Vis Sci 2011. 52(10):7697-7703.
214. Gorudko IV, Kostevich VA, Sokolov AV, Shamova EV, Buko IV, Konstantinova EE, Vasiliev VB, Cherenkevich SN, Panasenko OM. Functional activity of neutrophils in diabetes mellitus and coronary heart disease: role of myeloperoxidase in the development of oxidative stress. Bull Exp Biol Med 2012. 154(1):23-26.
215. Kuo JZ, Guo X, Klein R, Klein BE, Cui J, Rotter JI, Ipp E, Chen YD. Systemic soluble tumor necrosis factor receptors 1 and 2 are associated with severity of diabetic retinopathy in Hispanics. Ophthalmology 2012. 119(5):1041-1046.
216. Zorena K, Mysliwska J, Mysliwiec M, Balcerska A, Hak L, Lipowski P, Raczynska K. Serum TNF-alpha level predicts nonproliferative diabetic retinopathy in children. Mediators Inflamm 2007. 2007:92196.
217. Nowak M, Wielkoszynski T, Marek B, Kos-Kudla B, Swietochowska E, Sieminska L, Kajdaniuk D, Glogowska-Szelag J, Nowak K. Blood serum levels of vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1) and endothelial leucocyte adhesion molecule-1 (ELAM-1) in diabetic retinopathy. Clin Exp Med 2008. 8(3):159-164.
218. Klein BE, Knudtson MD, Tsai MY, Klein R. The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy: Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol 2009. 127(9):1175-1182.
219. Nguyen TT, Alibrahim E, Islam FM, Klein R, Klein BE, Cotch MF, Shea S, Wong TY. Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. Diabetes Care 2009. 32(9):1704-1709.
220. Peng D, Wang J, Zhang R, Tang S, Jiang F, Chen M, Yan J, Sun X, Wang T, Wang S, et al. C-reactive protein genetic variant is associated with diabetic retinopathy in Chinese patients with type 2 diabetes. BMC Endocr Disord 2015. 15:8.
221. Rajab HA, Baker NL, Hunt KJ, Klein R, Cleary PA, Lachin J, Virella G, Lopes-Virella MF. The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes. J Diabetes Complications 2015. 29(1):108-114.
222. Simo-Servat O, Hernandez C, Simo R. Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathy. Mediators Inflamm 2012. 2012:872978.
223. Hernandez C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simo R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 2005. 22(6):719-722.
224. Murugeswari P, Shukla D, Kim R, Namperumalsamy P, Stitt AW, Muthukkaruppan V. Angiogenic potential of vitreous from Proliferative Diabetic Retinopathy and Eales’ Disease patients. Plos One 2014. 9(10):e107551.
225. Murugeswari P, Shukla D, Rajendran A, Kim R, Namperumalsamy P, Muthukkaruppan V. Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales’ disease. Retina 2008. 28(6):817-824.
226. Barber AJ, Antonetti DA, Kern TS, Reiter CE, Soans RS, Krady JK, Levison SW, Gardner TW, Bronson SK. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci 2005. 46(6):2210-2218.
227. Zeng HY, Green WR, Tso MO. Microglial activation in human diabetic retinopathy. Arch Ophthalmol 2008. 126(2):227-232.
228. Zeng XX, Ng YK, Ling EA. Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci 2000. 17(3):463-471.
229. Deliyanti D, Zhang Y, Khong F, Berka DR, Stapleton DI, Kelly DJ, Wilkinson-Berka JL. FT011, a novel cardiorenal protective drug, reduces inflammation, gliosis and vascular injury in rats with diabetic retinopathy. Plos One 2015. 10(7):e0134392.
230. Xu K, Liu X, Yang F, Cui D, Shi Y, Shen C, Tang W, Yang T. PAI-1-675 4G/5G polymorphism in association with diabetes and diabetic complications susceptibility: a meta-analysis study. Plos One 2013. 8(11):e79150.
231. Azad N, Agrawal L, Emanuele NV, Klein R, Bahn GD, McCarren M, Reaven P, Hayward R, Duckworth W. Association of PAI-1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 2014. 37(2):501-506.
232. Polat SB, Ugurlu N, Yulek F, Simavli H, Ersoy R, Cakir B, Erel O. Evaluation of serum fibrinogen, plasminogen, alpha2-anti-plasmin, and plasminogen activator inhibitor levels (PAI) and their correlation with presence of retinopathy in patients with type 1 DM. J Diabetes Res 2014. 2014:317292.
233. Behl T, Kotwani A. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy. Pharmacol Res 2015. 99:137-148.
234. Han L, Zhang L, Xing W, Zhuo R, Lin X, Hao Y, Wu Q, Zhao J. The associations between VEGF gene polymorphisms and diabetic retinopathy susceptibility: a meta-analysis of 11 case-control studies. J Diabetes Res 2014. 2014:805801.
235. Praidou A, Androudi S, Brazitikos P, Karakiulakis G, Papakonstantinou E, Dimitrakos S. Angiogenic growth factors and their inhibitors in diabetic retinopathy. Curr Diabetes Rev 2010. 6(5):304-312.
236. Craword SE, Fitchev P, Veliceasa D, Volpert OV. The many facets of PEDF in drug discovery and disease: a diamond in the rough or split personality disorder? Expert Opin Drug Discov 2013. 8(7):769-792.
237. He X, Cheng R, Benyajati S, Ma JX. PEDF and its roles in physiological and pathological conditions: implication in diabetic and hypoxia-induced angiogenic diseases. Clin Sci (Lond) 2015. 128(11):805-823.
238. Yamagishi S, Matsui T. Pigment epithelium-derived factor (PEDF) and cardiometabolic disorders. Curr Pharm Des 2014. 20(14):2377-2386.
239. Jenkins A, Zhang SX, Gosmanova A, Aston C, Dashti A, Baker MZ, Lyons T, Ma JX. Increased serum pigment epithelium derived factor levels in type 2 diabetes patients. Diabetes Res Clin Pract 2008. 82(1):e5-e7.
240. Liu Y, Leo LF, McGregor C, Grivitishvili A, Barnstable CJ, Tombran-Tink J. Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice. Mol Med 2012. 18:1387-1401.
241. Kim KH, Lee MS. FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs. J Endocrinol 2015. 226(1):R1-R16.
242. Liu JJ, Foo JP, Liu S, Lim SC. The role of fibroblast growth factor 21 in diabetes and its complications: A review from clinical perspective. Diabetes Res Clin Pract 2015. 108(3):382-389.
243. Lin Y, Xiao YC, Zhu H, Xu QY, Qi L, Wang YB, Li XJ, Zheng ML, Zhong RS, Zhang Y, et al. Serum fibroblast growth factor 21 levels are correlated with the severity of diabetic retinopathy. J Diabetes Res 2014. 2014:929756.
244. Ong KL, Januszewski AS, O’Connell R, Buizen L, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Scott RS, Taskinen MR, et al. Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia 2015. 58(9):2035-2044.
245. Klaassen I, van Geest RJ, Kuiper EJ, van Noorden CJ, Schlingemann RO. The role of CTGF in diabetic retinopathy. Exp Eye Res 2015. 133:37-48.
246. Jaffa AA, Usinger WR, McHenry MB, Jaffa MA, Lipstiz SR, Lackland D, Lopes-Virella M, Luttrell LM, Wilson PW. Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J Clin Endocrinol Metab 2008. 93(5):1893-1900.
247. Wang B, Carter RE, Jaffa MA, Nakerakanti S, Lackland D, Lopes-Virella M, Trojanowska M, Luttrell LM, Jaffa AA. Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes. J Med Genet 2010. 47(6):391-397.
248. Wu M, Chen Y, Wilson K, Chirindel A, Ihnat MA, Yu Y, Boulton ME, Szweda LI, Ma JX, Lyons TJ. Intraretinal leakage and oxidation of LDL in diabetic retinopathy. Invest Ophthalmol Vis Sci 2008. 49(6):2679-2685.
249. Bucan K, Ivanisevic M, Zemunik T, Boraska V, Skrabic V, Vatavuk Z, Galetovic D, Znaor L. Retinopathy and nephropathy in type 1 diabetic patients-association with polymorphysms of vitamin D-receptor, TNF, Neuro-D and IL-1 receptor 1 genes. Coll Antropol 2009. 33(Suppl 2):99-105.
250. Cyganek K, Mirkiewicz-Sieradzka B, Malecki MT, Wolkow P, Skupien J, Bobrek J, Czogala M, Klupa T, Sieradzki J. Clinical risk factors and the role of VDR gene polymorphisms in diabetic retinopathy in Polish type 2 diabetes patients. Acta Diabetol 2006. 43(4):114-119.
251. Nebbioso M, Buomprisco G, Pascarella A, Pescosolido N. Modulatory effects of 1,25-dihydroxyvitamin D3 on eye disorders: a critical review. Crit Rev Food Sci Nutr 2015. In press.
252. Taverna MJ, Selam JL, Slama G. Association between a protein polymorphism in the start codon of the vitamin D receptor gene and severe diabetic retinopathy in C-peptidenegative type 1 diabetes. J Clin Endocrinol Metab 2005. 90(8):4803-4808.
253. Taverna MJ, Sola A, Guyot-Argenton C, Pacher N, Bruzzo F, Slama G, Reach G, Selam JL. Taq I polymorphism of the vitamin D receptor and risk of severe diabetic retinopathy. Diabetologia 2002. 45(3):436-442.
254. Zhong X, Du Y, Lei Y, Liu N, Guo Y, Pan T. Effects of vitamin D receptor gene polymorphism and clinical characteristics on risk of diabetic retinopathy in Han Chinese type 2 diabetes patients. Gene 2015. 566(2):212-216.
255. Ahmadieh H, Azar ST, Lakkis N, Arabi A. Hypovitaminosis d in patients with type 2 diabetes mellitus: a relation to disease control and complications. ISRN Endocrinol 2013. 2013:641098.
256. Aksoy H, Akcay F, Kurtul N, Baykal O, Avci B. Serum 1,25 dihydroxy vitamin D (1,25(OH)2D3), 25 hydroxy vitamin D (25(OH)D) and parathormone levels in diabetic retinopathy. Clin Biochem 2000. 33(1):47-51.
257. Alcubierre N, Valls J, Rubinat E, Cao G, Esquerda A, Traveset A, Granado-Casas M, Jurjo C, Mauricio D. Vitamin D deficiency Is associated with the presence and severity of diabetic retinopathy in type 2 diabetes mellitus. J Diabetes Res 2015. 2015:374178.
258. Bonakdaran S, Shoeibi N. Is there any correlation between vitamin D insufficiency and diabetic retinopathy? Int J Ophthalmol 2015. 8(2):326-331.
259. He R, Shen J, Liu F, Zeng H, Li L, Yu H, Lu H, Lu F, Wu Q, Jia W. Vitamin D deficiency increases the risk of retinopathy in Chinese patients with type 2 diabetes. Diabet Med 2014. 31(12):1657-1664.
260. Jee D, Han K, Kim EC. Inverse association between high blood 25-hydroxyvitamin D levels and diabetic retinopathy in a representative Korean population. Plos One 2014. 9(12):e115199.
261. Kaur H, Donaghue KC, Chan AK, Benitez-Aguirre P, Hing S, Lloyd M, Cusumano J, Pryke A, Craig ME. Vitamin D deficiency is associated with retinopathy in children and adolescents with type 1 diabetes. Diabetes Care 2011. 34(6):1400-1402.
262. Patrick PA, Visintainer PF, Shi Q, Weiss IA, Brand DA. Vitamin D and retinopathy in adults with diabetes mellitus. Arch Ophthalmol 2012. 130(6):756-760.
263. Payne JF, Ray R, Watson DG, Delille C, Rimler E, Cleveland J, Lynn MJ, Tangpricha V, Srivastava SK. Vitamin D insufficiency in diabetic retinopathy. Endocr Pract 2012. 18(2):185-193.
264. Reddy GB, Sivaprasad M, Shalini T, Satyanarayana A, Seshacharyulu M, Balakrishna N, Viswanath K, Sahay M. Plasma vitamin D status in patients with type 2 diabetes with and without retinopathy. Nutrition 2015. 31(7-8):959-963.
265. Shimo N, Yasuda T, Kaneto H, Katakami N, Kuroda A, Sakamoto F, Takahara M, Irie Y, Horikawa K, Miyashita K, et al. Vitamin D deficiency is significantly associated with retinopathy in young Japanese type 1 diabetic patients. Diabetes Res Clin Pract 2014. 106(2):e41-e43.
266. Poon M, Craig ME, Kaur H, Cusumano J, Sasongko MB, Wong TY, Donaghue KC. Vitamin D deficiency is not associated with changes in retinal geometric parameters in young people with type 1 diabetes. J Diabetes Res 2013. 2013:280691.
267. Herrmann M, Sullivan DR, Veillard AS, McCorquodale T, Straub IR, Scott R, Laakso M, Topliss D, Jenkins AJ, Blankenberg S, et al. Serum 25-hydroxyvitamin D: a predictor of macrovascular and microvascular complications in patients with type 2 diabetes. Diabetes Care 2015. 38(3):521-528.
268. Alele JD, Luttrell LM, Hollis BW, Luttrell DK, Hunt KJ. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis 2013. 228(2):502-507.
269. Joergensen C, Hovind P, Schmedes A, Parving HH, Rossing P. Vitamin D levels, microvascular complications, and mortality in type 1 diabetes. Diabetes Care 2011. 34(5):1081-1085.
270. McCully KS. Chemical pathology of homocysteine. I. Atherogenesis. Ann Clin Lab Sci 1993. 23(6):477-493.
271. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989. 114(5):473-501.
272. Marti-Carvajal AJ, Sola I, Lathyris D. Homocysteinelowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2015. 1:CD006612.
273. Bulum T, Blaslov K, Duvnjak L. Plasma homocysteine is associated with retinopathy in type 1 diabetic patients in the absence of nephropathy. Semin Ophthalmol 2015. 2015:1-5.
274. Cho HC. The relationship among homocysteine, bilirubin, and diabetic retinopathy. Diabetes Metab J 2011. 35(6):595-601.
275. Lim CP, Loo AV, Khaw KW, Sthaneshwar P, Khang TF, Hassan M, Subrayan V. Plasma, aqueous and vitreous homocysteine levels in proliferative diabetic retinopathy. Br J Ophthalmol 2012. 96(5):704-707.
276. Satyanarayana A, Balakrishna N, Pitla S, Reddy PY, Mudili S, Lopamudra P, Suryanarayana P, Viswanath K, Ayyagari R, Reddy GB. Status of B-vitamins and homocysteine in diabetic retinopathy: association with vita min-B12 deficiency and hyperhomocysteinemia. Plos One 2011. 6(11):e26747.
277. Xu C, Wu Y, Liu G, Liu X, Wang F, Yu J. Relationship between homocysteine level and diabetic retinopathy: a systematic review and meta-analysis. Diagn Pathol 2014. 9:167.
278. Kilic S, Yilmaz N, Zulfikaroglu E, Erdogan G, Aydin M, Batioglu S. Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecol Endocrinol 2011. 27(9):622-629.
279. Sahin M, Tutuncu NB, Ertugrul D, Tanaci N, Guvener ND. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus. J Diabetes Complications 2007. 21(2):118-123.
280. Kuo JZ, Wong TY, Rotter JI. Challenges in elucidating the genetics of diabetic retinopathy. JAMA Ophthalmol 2014. 132(1):96-107.
281. Awata T, Yamashita H, Kurihara S, Morita-Ohkubo T, Miyashita Y, Katayama S, Mori K, Yoneya S, Kohda M, Okazaki Y, et al. A genome-wide association study for diabetic retinopathy in a Japanese population: potential association with a long intergenic non-coding RNA. Plos One 2014. 9(11):e111715.
282. Chang YC, Chang EY, Chuang LM. Recent progress in the genetics of diabetic microvascular complications. World J Diabetes 2015. 6(5):715-725.
283. Haycock PC, Heydon EE, Kaptoge S, Butterworth AS, Thompson A, Willeit P. Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis. BMJ 2014. 349:g4227.
284. McCord RA, Broccoli D. Telomeric chromatin: roles in aging, cancer and hereditary disease. Mutat Res 2008. 647(1-2):86-93.
285. Minamino T, Komuro I. Vascular cell senescence: contribution to atherosclerosis. Circ Res 2007. 100(1):15-26.
286. Al-Attas OS, Al-Daghri NM, Alokail MS, Alkharfy KM, Alfadda AA, McTernan P, Gibson GC, Sabico SB, Chrousos GP. Circulating leukocyte telomere length is highly heritable among families of Arab descent. BMC Med Genet 2012. 13:38.
287. Balasubramanyam M, Adaikalakoteswari A, Monickaraj SF, Mohan V. Telomere shortening and metabolic/vascular diseases. Indian J Med Res 2007. 125(3):441-450.
288. Gardner JP, Li S, Srinivasan SR, Chen W, Kimura M, Lu X, Berenson GS, Aviv A. Rise in insulin resistance is associated with escalated telomere attrition. Circulation 2005. 111(17):2171-2177.
289. Fyhrquist F, Tiitu A, Saijonmaa O, Forsblom C, Groop PH. Telomere length and progression of diabetic nephropathy in patients with type 1 diabetes. J Intern Med 2010. 267(3):278-286.
290. Astrup AS, Tarnow L, Jorsal A, Lajer M, Nzietchueng R, Benetos A, Rossing P, Parving HH. Telomere length predicts all-cause mortality in patients with type 1 diabetes. Diabetologia 2010. 53(1):45-48.
291. Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, Packard CJ, Samani NJ. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007. 369(9556):107-114.
292. Brugere JF, Cornillot E, Metenier G, Vivares CP. Occurence of subtelomeric rearrangements in the genome of the microsporidian parasite Encephalitozoon cuniculi, as revealed by a new fingerprinting procedure based on twodimensional pulsed field gel electrophoresis. Electrophoresis 2000. 21(12):2576-2581.
293. Nersisyan L, Arakelyan A. Computel: computation of mean telomere length from whole-genome next-generation sequencing data. Plos One 2015. 10(4):e0125201.
294. Cooper ME, El-Osta A. Epigenetics: mechanisms and implications for diabetic complications. Circ Res 2010. 107(12):1403-1413.
295. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008. 205(10):2409-2417.
296. Keating ST, El-Osta A. Epigenetics and metabolism. Circ Res 2015. 116(4):715-736.
297. Mishra M, Zhong Q, Kowluru RA. Epigenetic modifications of Keap1 regulate its interaction with the protective factor Nrf2 in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 2014. 55(11):7256-7265.
298. Perrone L, Matrone C, Singh LP. Epigenetic modifications and potential new treatment targets in diabetic retinopathy. J Ophthalmol 2014. 2014:789120.
299. Reddy MA, Zhang E, Natarajan R. Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia 2015. 58(3):443-455.
300. Hardikar AA, Satoor SN, Karandikar MS, Joglekar MV, Puranik AS, Wong W, Kumar S, Limaye A, Bhat DS, Januszewski AS, et al. Multigenerational undernutrition increases susceptibility to obesity and diabetes that is not reversed after dietary recuperation. Cell Metab 2015. 22(2):312-319.
301. Zhao S, Li J, Wang N, Zheng B, Li T, Gu Q, Xu X, Zheng Z. Fenofibrate suppresses cellular metabolic memory of high glucose in diabetic retinopathy via a sirtuin 1-dependent signalling pathway. Mol Med Rep 2015. 12(4):6112-6118.
302. Mastropasqua R, Toto L, Cipollone F, Santovito D, Carpineto P, Mastropasqua L. Role of microRNAs in the modulation of diabetic retinopathy. Prog Retin Eye Res 2014. 43:92-107.
303. Weiland M, Gao XH, Zhou L, Mi QS. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol 2012. 9(6):850-859.
304. Ragusa M, Caltabiano R, Russo A, Puzzo L, Avitabile T, Longo A, Toro MD, Di Pietro C, Purrello M, Reibaldi M. MicroRNAs in vitreus humor from patients with ocular diseases. Mol Vis 2013. 19:430-440.
305. Dunmire JJ, Lagouros E, Bouhenni RA, Jones M, Edward DP. MicroRNA in aqueous humor from patients with cataract. Exp Eye Res 2013. 108:68-71.
306. Li J, Chen Y, Qin X, Wen J, Ding H, Xia W, Li S, Su X, Wang W, Li H, et al. MiR-138 downregulates miRNA processing in HeLa cells by targeting RMND5A and decreasing Exportin-5 stability. Nucleic Acids Res 2014. 42(1):458-474.
307. Liu J, Feener EP. Plasma kallikrein-kinin system and diabetic retinopathy. Biol Chem 2013. 394(3):319-328.
308. Lu CH, Lin ST, Chou HC, Lee YR, Chan HL. Pro teomic analysis of retinopathy-related plasma biomarkers in diabetic patients. Arch Biochem Biophys 2013. 529(2):146-156.
309. Monteiro JP, Santos FM, Rocha AS, Castro-de-Sousa JP, Queiroz JA, Passarinha LA, Tomaz CT. Vitreous humor in the pathologic scope: insights from proteomic approaches. Proteomics Clin Appl 2015. 9(1-2):187-202.
310. Murthy KR, Goel R, Subbannayya Y, Jacob HK, Murthy PR, Manda SS, Patil AH, Sharma R, Sahasrabuddhe NA, Parashar A, et al. Proteomic analysis of human vitreous humor. Clin Proteomics 2014. 11(1):29.
311. Semba RD, Huang H, Lutty GA, Van Eyk JE, Hart GW. The role of O-GlcNAc signaling in the pathogenesis of diabetic retinopathy. Proteomics Clin Appl 2014. 8(3-4):218-231.
312. Tian H, Wang L, Cai R, Zheng L, Guo L. Identification of protein network alterations upon retinal ischemiareperfusion injury by quantitative proteomics using a Rattus norvegicus model. Plos One 2014. 9(12):e116453.
313. Wang H, Feng L, Hu J, Xie C, Wang F. Differentiating vitreous proteomes in proliferative diabetic retinopathy using high-performance liquid chromatography coupled to tandem mass spectrometry. Exp Eye Res 2013. 108:110-119.
314. Li X, Luo X, Lu X, Duan J, Xu G. Metabolomics study of diabetic retinopathy using gas chromatography-mass spectrometry: a comparison of stages and subtypes diagnosed by Western and Chinese medicine. Mol Biosyst 2011. 7(7):2228-2237.
315. Barba I, Garcia-Ramirez M, Hernandez C, Alonso MA, Masmiquel L, Garcia-Dorado D, Simo R. Metabolic fingerprints of proliferative diabetic retinopathy: an 1H-NMR-based metabonomic approach using vitreous humor. Invest Ophthalmol Vis Sci 2010. 51(9):4416-4421.
316. Csosz E, Boross P, Csutak A, Berta A, Toth F, Poliska S, Torok Z, Tozser J. Quantitative analysis of proteins in the tear fluid of patients with diabetic retinopathy. J Proteomics 2012. 75(7):2196-2204.